13F Holdings
中文EN

RXRX RECURSION PHARMACEUTICALS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1601830 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY56.2%
TTM net income YoY33.5%
TTM EPS YoY53.3%
Revenue 3-yr CAGR12.9%
Net income 3-yr CAGR—

Margins

Gross margin29.2%
Operating margin-725.4%
Net margin-697.1%
FCF margin-458.0%
EBITDA margin-617.2%

Returns

ROE-48.7%
ROA-36.3%
ROIC (approx.)-101.8%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets25.9%
Debt / equity0.01x
Current ratio5.01x
Interest coverage-541.56x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.6%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$74.68M$58.84M$44.58M$39.84M$10.18M
Cost of revenue$70.95M$45.24M$42.59M$48.27M$0
Gross profit$3.73M$13.60M$1.99M-$8.43M$10.18M
R&D expense$475.27M$314.42M$241.23M$155.70M$135.27M
SG&A expense$176.59M$178.18M$110.82M$81.60M$57.68M
Operating income-$648.13M-$479.00M-$350.06M-$245.73M-$182.78M
Interest expense$1.81M$1.57M$97,000$55,000$2.95M
Pretax income-$644.89M-$464.79M-$332.13M-$239.48M-$186.48M
Income tax-$136,000-$1.13M-$4.06M$0$0
Net income-$644.76M-$463.66M-$328.07M-$239.48M-$186.48M
EBITDA-$564.43M-$442.51M-$325.66M-$233.97M-$174.37M
EPS (basic)-1.44-1.69-1.58-1.36-1.49
EPS (diluted)-1.44-1.69-1.58-1.36-1.49
Weighted avg. shares (diluted)447.45M274.21M207.85M175.54M125.35M
Balance sheet
Cash & equivalents$743.29M$603.02M$401.43M$559.11M$295.35M
Short-term investments———$0$231.45M
Receivables———$0$34,000
Current assets$812.85M$714.27M$438.14M$569.81M$534.72M
PP&E, net$103.93M$141.06M$86.51M$88.19M$64.72M
Goodwill$162.16M$148.87M$52.06M$801,000$801,000
Intangibles$309.90M$335.86M$36.44M$1.31M$1.39M
Total assets$1.47B$1.45B$653.70M$701.29M$610.35M
Current liabilities$147.71M$187.47M$93.17M$100.27M$46.66M
Short-term debt$9.09M$8.43M$41,000——
Long-term debt$9.56M$19.02M$1.10M—$723,000
Total debt$18.66M$27.45M$1.14M—$723,000
Total liabilities$343.26M$413.82M$190.26M$215.48M$67.41M
Shareholders' equity$1.13B$1.03B$463.44M$485.81M$542.94M
Net debt-$724.64M-$575.58M-$400.28M—-$294.63M
Shares outstanding528.18M396.80M234.27M191.02M170.27M
Cash flow statement
Operating cash flow-$371.81M-$359.17M-$287.78M-$83.52M-$158.61M
Capital expenditure$6.47M$13.70M$11.96M$37.06M$39.80M
Free cash flow-$378.28M-$372.87M-$299.74M-$120.58M-$198.41M
Investing cash flow-$16.87M$260.06M-$10.23M$193.25M-$271.74M
Financing cash flow$521.53M$304.12M$140.13M$154.34M$458.54M
Depreciation & amortization$83.70M$36.49M$24.40M$11.76M$8.40M
Stock-based compensation$111.22M$81.69M$53.50M$27.91M$14.84M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.